We will have limited support available from December 23rd, 2024 through January 1st, 2025.
All inquiries received during this time will be processed as quickly as staff availability allows, with normal availability beginning January 2nd.
We appreciate your understanding and patience. Happy Holidays!

Flow Cytometry

  • What’s the Tea on SNE?

    Stochastic Neighbor Embedding (SNE) is a family of algorithms that create a low-dimensional representation of high-dimensional data by randomly initializing positions for each data point in low-dimensional space, and then optimizing their positions iteratively to better approximate the relationships between those data points and a sampling of their neighbors in the original high dimensional space. The defining characteristic of SNE algorithms is that the appropriate place for each data point in the low dimensional space is represented as a probability distribution for each of its neighbors.

    T...

    Dec 03, 2019   |   Flow Cytometry ,   scRNA-Seq

  • Why Cells Die Young: Researchers Investigate Plasma Cell Lifespans

    Vaccines provide immunity by stimulating a set of naive B cells to become antibody-producing plasma cells against a specific pathogen. However, plasma cells have varying lifespans, which is why some vaccines, such as measles and HPV, require boosters, because once all the pathogen-specific plasma cells die, immunity ends. What drives this variation? How can we prolong a plasma cell’s life? Can longer-living plasma cells help create enduring vaccines? Could shortening a plasma cell’s lifespan prevent damage to an autoimmune patient? A team of researchers, led by Wing Lam of Washington University, sought to answer these questions about plasma cell longevity in their recent study.

    May 22, 2019   |   Flow Cytometry ,   scRNA-Seq

  • Drawn together: Remodeling the puzzling mechanisms of Idiopathic pulmonary fibrosis

    Idiopathic pulmonary fibrosis (IPF), a chronic lung disease claiming approximately 30,000 to 40,000 victims every year, is characterized by rapid lung degeneration and a dismal median survival of 3-5 years after diagnosis. Despite a clear need for treatments that can improve this prognosis, there are currently only two therapies available for the treatment of IPF. While these two therapies have been shown to slow disease progression, neither treatment can actually halt lung degeneration or reverse lung tissue remodeling.

    Mar 26, 2019   |   Flow Cytometry ,   scRNA-Seq